Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.
We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...
StockStory.org on MSN1d
Why Sarepta Therapeutics (SRPT) Shares Are Sliding TodayShares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...
Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for ...
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...
Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
In a report released today, Louise Chen from Scotiabank maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback